SHANGHAI and GAITHERSBURG, Md. , Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3

SHANGHAI and GAITHERSBURG, Md. , Feb. 24, 2021 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in

SHANGHAI and GAITHERSBURG, Md. , Feb. 10, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China

SHANGHAI and GAITHERSBURG, Md. , Feb. 9, 2021 /PRNewswire/ -- A registered follow-on public offering by certain pre-IPO shareholders (the "Selling Shareholders") of 3,283,950 American depositary shares (the "ADSs" and such offering, the "ADS Offering") of I-Mab (the "Company") (Nasdaq: IMAB ), a

SHANGHAI and GAITHERSBURG, Md. , Feb. 5, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the commencement of a proposed registered underwritten

- First patient dosed in a combination study with anti-PD1 in China - Topline results from U.S. phase 1 study demonstrate safety and clinical activity - Data from preclinical and clinical studies to be presented at conferences this year SHANGHAI and GAITHERSBURG, Md. , Feb.

SHANGHAI and GAITHERSBURG, Md. , Feb. 4, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB ), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in a phase 2

SHANGHAI, China and PLANEGG/ MUNICH, Germany , Jan. 25, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB ), and MorphoSys (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety,